Cargando…

PB1770: CHARACTERIZATION OF THE MUTATIONAL PROFILE OF PATIENTS WITH CBF-AML - HETEROGENEITY AND IMPACT ON THE PROGNOSIS

Detalles Bibliográficos
Autores principales:	Motyko, Ekaterina, Kirienko, Anna, Kustova, Daria, Rajabova, Asiyat, Uspenskaya, Olga, Karyagina, Elena, Shuvaev, Vasiliy, Voloshin, Sergey, Sidorkevich, Sergey, Martynkevich, Irina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430096/ http://dx.doi.org/10.1097/01.HS9.0000973936.05327.24

Ejemplares similares

PB2175: NEXT-GENERATION SEQUENCING IN THE DIAGNOSIS, PROGNOSIS AND FEATURES OF THE COURSE OF THE DISEASE IN PATIENTS WITH PH-NEGATIVE MYELOPROLIFERATIVE NEOPLASMS
por: Kirienko, Anna, et al.
Publicado: (2023)

PB2390: STUDY OF GENETIC ALTERATIONS USING A CUSTOM LYMPHOID TARGETED NGS PANEL IN PATIENTS WITH FOLLICULAR LYMPHOMA: A PILOT STUDY
por: Куневич, Евгений, et al.
Publicado: (2023)

PB1856: MUTATION STATUS AND ALLELE BURDEN OF FLT3-ITD IN ACUTE MYELOID LEUKEMIA
por: Radzhabova, Asiyat, et al.
Publicado: (2023)

P660: NEXT-GENERATION SEQUENCING (NGS) FOR DETECTING BCR::ABL-INDEPENDENT MUTATIONS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA WITH RESISTANCE TO TYROSINE KINASE INHIBITOR TREATMENT
por: Kustova, Daria, et al.
Publicado: (2023)

PB1916: DETECTION OF AUTOANTIBODIES TO NEUTROPHIL AND ERYTHROCYTE ANTIGENS IN PATIENTS WITH CHRONIC LYMPHOPROLIFERATIVE DISEASES
por: Irina, Krobinets, et al.
Publicado: (2023)

P1573: EVALUATION OF THE EFFICACY OF SARS-COV-2 VACCINATION IN PATIENTS WITH FOLLICULAR LYMPHOMA DURING THE ERA OF THE COVID-19 PANDEMIC
por: Куневич, Евгений, et al.
Publicado: (2023)

PB1770: REASONS FOR CHANGES OF BONE FORMATION PROCESSES IN CHILDREN WITH ALL LIVING IN RADIOACTIVELY CONTAMINATED TERRITORIES OF UKRAINE
por: Bruslova, K., et al.
Publicado: (2022)

Transcription of WNT Genes in Hematopoietic Niche’s Mesenchymal Stem Cells in Multiple Myeloma Patients with Different Responses to Treatment
por: Enukashvily, Natella I., et al.
Publicado: (2023)

PB2060: THE RESULTS OF A FOUR YEARS LONG OBSERVATION OF APLASTIC AMENIA PATIENTS DEPENDING ON A PROGRAM OF IMMUNOSUPPRESSIVE THERAPY
por: Chebykina, Daria, et al.
Publicado: (2023)

PB1836: LOSS OF HETEROZYGOSITY IN AML PATIENTS WITH INV(16)
por: Bessmertniy, Dmitry, et al.
Publicado: (2023)

PB2171: POTENTIAL ROLE OF FACTOR XII POLYMORPHISM IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS
por: Efremova, Elizaveta, et al.
Publicado: (2023)

PB1800: CLINICAL CHARACTERISTICS AND MUTATION LANDSCAPE OF TRISOMY AML
por: Lam, Stephen S Y, et al.
Publicado: (2023)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

PB1793: NEUTROPHIL TO LYMPHOCYTE RATIO AS A PROGNOSTIC FACTOR IN AML AND MDS
por: Van Oorschot, V., et al.
Publicado: (2022)

PB1761: PRECLINICAL EVALUATION OF THE MENIN INHIBITOR ZIFTOMENIB IN PRIMARY AML SPECIMENS
por: Stevens, Brett, et al.
Publicado: (2023)

PB1783: IDENTIFICATION OF RAMAN SPECTROSCOPIC SIGNATURE OF IDH MUTATIONS IN AML IN VITRO MODEL
por: Laskowska, P., et al.
Publicado: (2022)

PB1791: SLFN11 REGULATES MULTIPLE PATHWAYS THAT ARE IMPORTANT FOR TREATMENT RESPONSE IN AML
por: Small, Sara, et al.
Publicado: (2023)

PB1896: ACUTE MYELOID LEUKEMIA (AML): REAL-WORLD DATA FROM LEBANON
por: Nasr, Lewis, et al.
Publicado: (2023)

PB1768: MICRORNA SIGNATURES IMPLY A ROLE FOR FOXO IN AML CHEMO-RESISTANCE
por: Reichelt, Paula, et al.
Publicado: (2023)

PB1866: IS ALLO-HSCT IN CR1 NECESSARY FOR AML PATIENTS WITH MRD NEGATIVITY ACHIEVED AFTER THE FIRST INDUCTION COURSE? RUSSIAN PROSPECTIVE MULTICENTER RANDOMIZED TRIAL IN AML PATIENTS UNDER THE AGE OF 60
por: Parovichnikova, Elena, et al.
Publicado: (2023)

PB2461: CONDITIONING REGIMEN AND SUBPOPULATION COMPOSITION OF AUTOGRAFT LYMPHOCYTES IN PATIENTS WITH MULTIPLE MYELOMA
por: Kostroma, Ivan, et al.
Publicado: (2023)

PB1841: A NEW APPROACH IN ACUTE MYELOID LEUKEMIA (AML): SAMATYA-PREDICTING SCORE
por: Serin, I., et al.
Publicado: (2022)

PB1808: EPIGENETIC INHIBITOR SCREEN TO IDENTIFY THERAPEUTIC CANDIDATES FOR MNX1-OVEREXPRESSING AML
por: Kelekci, Simge, et al.
Publicado: (2023)

PB1787: PLZF-RARΑ ENHANCES METABOLIC PLASTICITY AND ROS SCAVENGING IN AML CELLS
por: Zaza, Alessandra, et al.
Publicado: (2023)

PB1966: HEMOPOIETIC NICHE IMPAIRMENT IN TREATED MULTIPLE MYELOMA PATIENTS
por: Semenova, N. Y., et al.
Publicado: (2022)

PB1838: TOXICITY AND OUTCOME OF HIGH DOSE CYTARABINE (18 G/M2) FOR AML CONSOLIDATION.
por: Lopes, L., et al.
Publicado: (2022)

PB1812: CO-MUTATION PROFILE IN A REAL-LIFE COHORT OF ACUTE MYELOID LEUKEMIA (AML)
por: Piras, Giovanna, et al.
Publicado: (2023)

PB1852: COMPARISON OF CLINICAL CHARACTERISTICS OF ADULT CHILEAN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML), ACCORDING TO THEIR HEALTH CARE SYSTEM: ANALYSIS WITHIN THE FRAMEWORK OF THE PTHEMA AML REGISTRY
por: Romero, Monica, et al.
Publicado: (2023)

PB1804: CLINICAL AND DEMOGRAFIC RELATIONS OF BAALC GENE OVEREXPRESSION IN AML PATIENTS - A SINGLE-CENTER OBSERVATIONS
por: Aleksov, E., et al.
Publicado: (2022)

PB1795: MESENCHYMAL STROMAL CELL-DEPENDENT ADHESION PATHWAYS PROTECT AML CELLS FROM VENETOCLAX-INDUCED APOPTOSIS
por: Ciciarello, Marilena, et al.
Publicado: (2023)

PB1820: CD47-BLOCKER TTI-622 COMBINED WITH AZACITIDINE IN PATIENTS WITH TP53-MUTATED ACUTE MYELOID LEUKEMIA (AML) AND WITH AZACITIDINE + VENETOCLAX IN ELDERLY OR UNFIT PATIENTS WITH TP53-WILDTYPE AML
por: Daver, N., et al.
Publicado: (2022)

PB2413: SALVAGE THERAPY WITH VENETOCLAX AND A HYPOMETHYLATING AGENT FOR PATIENTS WITH AML RELAPSE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
por: Shaforostova, Inna, et al.
Publicado: (2023)

PB1797: THE PROGNOSTIC SIGNIFICANCE OF BCAT1 ON NPM1+FLT3-ITD+ AML PATIENTS AND RELATED MOLECULAR MECHANISMS
por: Pan, Xinan, et al.
Publicado: (2023)

PB1788: A SCREENING OF DONATED CHEMICAL PROBES TO IDENTIFY NOVEL THERAPEUTIC OPTIONS FOR ACUTE MYELOID LEUKEMIA (AML) IN CHILDHOOD
por: Laszig, Stephanie, et al.
Publicado: (2023)

PB1772: HIGH SLIT2 LEVELS ARE ASSOCIATED WITH GMP LIKE AML AND TREATMENT WITH RECOMBINANT SLIT2 INHIBITS LEUKEMOGENESIS
por: Simoes, Luise Araujo de Albuquerque, et al.
Publicado: (2023)

PB1777: THE AUTOMATED DATABASE-GUIDED STUDY OF THE PHENOTYPIC PROFILE IN CD34+ CD117+ HLADR+ PRECURSORS PROVIDES A SIMPLE AND RELIABLE STRATEGY FOR RAPID IDENTIFICATION OF CBF-MYH11+ ACUTE MYELOID LEUKEMIA.
por: Piñero, Paula, et al.
Publicado: (2023)

PB1772: IN-VITRO APOPTOTIC EFFECT OF NATURALLY OCCURRING COMPOUNDS, PIPERINE AND ASCORBIC ACID ON ACUTE MYELOID LEUKAEMAI (AML) CELL LINE.
por: Aljohani, R., et al.
Publicado: (2022)

PB1831: UTILITY OF FLT3 INHIBITORS IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML) AND T(6;9)(P22;Q34)
por: Ong, F., et al.
Publicado: (2022)

PB2411: THE EFFICACY OF MODIFIED MELPHALAN AND BUSULFAN-BASED CONDITIONING REGIMEN FOR AUTOLOGOUS-HSCT IN LOW-RISK AND INTERMEDIATE-RISK AML PATIENTS
por: Zhai, Weihua, et al.
Publicado: (2023)

PB1905: REAL-WORLD EXPERIENCE OF LOW-DOSE VENETOCLAX WITH AZACITIDINE FOR UNFIT AML PATIENTS(≥60Y) WITH LOW LEUKOCYTE COUNT
por: Wei, Wenjian, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_dfva71dnjdvqkcm5f76tsfrk3v